PerkinElmer Prices Offering of Senior Notes
September 08 2021 - 10:30PM
Business Wire
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to
innovating for a healthier world, announced today that it has
priced an offering of $500.0 million aggregate principal amount of
0.550% Senior Notes due 2023 at an issue price of 99.964% of the
principal amount, $800.0 million aggregate principal amount of
0.850% Senior Notes due 2024 at an issue price of 99.938% of the
principal amount, $500.0 million aggregate principal amount of
1.900% Senior Notes due 2028 at an issue price of 99.928% of the
principal amount and $500.0 million aggregate principal amount of
2.250% Senior Notes due 2031 at an issue price of 99.697% of the
principal amount.
The issuance of the notes is expected to close on September 10,
2021, subject to the satisfaction of customary closing conditions.
The notes will pay interest on a semi-annual basis.
PerkinElmer plans to use the net proceeds of the offering to pay
a portion of the cash consideration payable for its planned
acquisition of BioLegend, Inc.
The joint book-running managers for the offering are Goldman
Sachs & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities
LLC and Wells Fargo Securities, LLC.
The offering is being made pursuant to an effective registration
statement on Form S-3 (including a prospectus) filed with the U.S.
Securities and Exchange Commission (“SEC”). Prospective investors
should read the prospectus forming a part of that registration
statement and the prospectus supplement related to the offering and
the other documents that PerkinElmer has filed with the SEC for
more complete information about the company and this offering.
These documents are available at no charge by visiting EDGAR on the
SEC website at www.sec.gov. Alternatively, copies of the prospectus
supplement and the accompanying prospectus relating to the offering
can be obtained by calling one of the joint book-running managers
at the following: Goldman Sachs & Co. LLC at 1-866-471-2526 or
by emailing Prospectus-NY@ny.email.gs.com, BofA Securities, Inc.
toll-free at 1-800-294-1322, J.P. Morgan Securities LLC collect at
1-212-834-4533 or Wells Fargo Securities, LLC toll-free at
1-800-645-3751.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any
offer, solicitation or sale of the notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
About PerkinElmer
PerkinElmer, Inc. is a global leader focused on innovating for a
healthier world. The Company reported revenue of approximately $3.8
billion in 2020, has more than 14,000 employees serving customers
in 190 countries, and is a component of the S&P 500 Index.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about PerkinElmer’s
intended use of proceeds, including its acquisition of BioLegend,
Inc. These statements involve a number of risks and uncertainties
that could cause actual results to differ materially from currently
anticipated results, including risks and uncertainties relating to
capital markets conditions and completion of the offering.
Additional important factors and information regarding
PerkinElmer’s business that could cause actual results to differ
materially from those indicated by such forward-looking statements
are set forth in the prospectus and preliminary prospectus
supplement dated September 8, 2021 related to the offering, which
is on file with the SEC and available in the “Investors” section of
the Company’s website under the heading “SEC Filings,” and the
documents incorporated by reference into the prospectus and
prospectus supplement. While PerkinElmer may elect to update
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so, even if
circumstances change and, therefore, you should not rely on these
forward-looking statements as representing the Company’s views as
of any date subsequent to today.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908006184/en/
Investor Relations: PerkinElmer, Inc. Stephen Willoughby,
781-663-5677 stephen.willoughby@perkinelmer.com
Media Relations: PerkinElmer, Inc. Chet Murray, 781-462-5126
chet.murray@perkinelmer.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Mar 2024 to Apr 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Apr 2023 to Apr 2024